588 related articles for article (PubMed ID: 17565646)
1. Predictors for squamous re-epithelialization of Barrett's esophagus after endoscopic biopsy.
Amano Y; Kushiyama Y; Yuki T; Takahashi Y; Chinuki D; Ishimura N; Furuta K; Ishihara S; Adachi K; Maruyama R; Kinoshita Y
J Gastroenterol Hepatol; 2007 Jun; 22(6):901-7. PubMed ID: 17565646
[TBL] [Abstract][Full Text] [Related]
2. REG Ialpha protein expression in Barrett's esophagus.
Chinuki D; Amano Y; Ishihara S; Moriyama N; Ishimura N; Kazumori H; Kadowaki Y; Takasawa S; Okamoto H; Kinoshita Y
J Gastroenterol Hepatol; 2008 Feb; 23(2):296-302. PubMed ID: 18289358
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of and risk factors for Barrett's esophagus with intestinal predominant mucin phenotype.
Amano Y; Kushiyama Y; Yuki T; Takahashi Y; Moriyama I; Fukuhara H; Ishimura N; Furuta K; Ishihara S; Adachi K; Maruyama R; Kinoshita Y
Scand J Gastroenterol; 2006 Aug; 41(8):873-9. PubMed ID: 16803684
[TBL] [Abstract][Full Text] [Related]
4. Fatty acid synthase expression in Barrett's esophagus: implications for carcinogenesis.
Ishimura N; Amano Y; Sanchez-Siles AA; Fukuhara H; Takahashi Y; Uno G; Tamagawa Y; Mishima Y; Yuki T; Ishihara S; Kinoshita Y
J Clin Gastroenterol; 2011 Sep; 45(8):665-72. PubMed ID: 21325951
[TBL] [Abstract][Full Text] [Related]
5. What is the clinical significance of stromal angiogenesis in Barrett's esophagus?
Moriyama N; Amano Y; Mishima Y; Okita K; Takahashi Y; Yuki T; Ishimura N; Ishihara S; Kinoshita Y
J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S210-5. PubMed ID: 19120900
[TBL] [Abstract][Full Text] [Related]
6. Barrett's oesophagus with predominant intestinal metaplasia correlates with superficial cyclo-oxygenase-2 expression, increased proliferation and reduced apoptosis: changes that are partially reversed by non-steroidal anti-inflammatory drugs usage.
Amano Y; Ishihara S; Kushiyama Y; Yuki T; Takahashi Y; Chinuki D; Miyake T; Miyaoka Y; Rumi MA; Ishimura N; Adachi K; Kinoshita Y
Aliment Pharmacol Ther; 2004 Oct; 20(7):793-802. PubMed ID: 15379840
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression.
Kahaleh M; Van Laethem JL; Nagy N; Cremer M; Devière J
Endoscopy; 2002 Dec; 34(12):950-5. PubMed ID: 12471537
[TBL] [Abstract][Full Text] [Related]
8. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3420-6. PubMed ID: 10606297
[TBL] [Abstract][Full Text] [Related]
9. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
[TBL] [Abstract][Full Text] [Related]
10. Predictors of recurrent specialized intestinal metaplasia after complete laser ablation.
Fisher RS; Bromer MQ; Thomas RM; Cohen S; Krevsky B; Horwitz B; Glazier KD; Das K; Das KM
Am J Gastroenterol; 2003 Sep; 98(9):1945-51. PubMed ID: 14499770
[TBL] [Abstract][Full Text] [Related]
11. Mucin expression and proliferating cell index of esophageal Barrett's adenocarcinoma.
Yamamoto S; Kijima H; Hara T; Chino O; Shimada H; Tanaka M; Inokuchi S; Makuuchi H
Int J Mol Med; 2005 Sep; 16(3):375-80. PubMed ID: 16077942
[TBL] [Abstract][Full Text] [Related]
12. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.
Sharma P; Sampliner RE; Camargo E
Am J Gastroenterol; 1997 Apr; 92(4):582-5. PubMed ID: 9128303
[TBL] [Abstract][Full Text] [Related]
13. The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy.
El-Serag HB; Aguirre T; Kuebeler M; Sampliner RE
Aliment Pharmacol Ther; 2004 Jun; 19(12):1255-60. PubMed ID: 15191506
[TBL] [Abstract][Full Text] [Related]
14. Squamous islands in Barrett's esophagus: what lies underneath?
Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
Am J Gastroenterol; 1998 Mar; 93(3):332-5. PubMed ID: 9517634
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy for Barrett's esophagus: clinical update.
Overholt BF; Panjehpour M
Am J Gastroenterol; 1996 Sep; 91(9):1719-23. PubMed ID: 8792687
[TBL] [Abstract][Full Text] [Related]
16. High power setting argon plasma coagulation for the eradication of Barrett's esophagus.
Pereira-Lima JC; Busnello JV; Saul C; Toneloto EB; Lopes CV; Rynkowski CB; Blaya C
Am J Gastroenterol; 2000 Jul; 95(7):1661-8. PubMed ID: 10925965
[TBL] [Abstract][Full Text] [Related]
17. Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy.
Eloubeidi MA; Provenzale D
Am J Gastroenterol; 1999 Apr; 94(4):937-43. PubMed ID: 10201460
[TBL] [Abstract][Full Text] [Related]
18. Esophageal squamous carcinoma in five patients with Barrett's esophagus.
Paraf F; Fléjou JF; Potet F; Molas G; Fékété F
Am J Gastroenterol; 1992 Jun; 87(6):746-50. PubMed ID: 1590313
[TBL] [Abstract][Full Text] [Related]
19. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis.
Weston AP; Sharma P; Mathur S; Banerjee S; Jafri AK; Cherian R; McGregor D; Hassanein RS; Hall M
Am J Gastroenterol; 2004 Sep; 99(9):1657-66. PubMed ID: 15330898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
